Today Naobios, a contract development and manufacturing company that provides bioprocess development and production of clinical batches of virus-based products, announced that it has received a €1.7M grant from the Bill & Melinda Gates Foundation to support vaccine development.
Naobios will manufacture a human viral challenge agent that will be used to evaluate the effectiveness of vaccines in preventing infections and to accelerate the vaccine development process.
Naobios has manufactured an Omicron variant SARS-CoV-2 virus, which will be used to conduct a Controlled Human Infection Model (CHIM) study.
The aim is to support the development of low-cost, effective mucosal vaccines to stop respiratory virus transmission, which, with greater breadth, can be deployed to outbreak areas, typically in low to middle-income countries, to prevent widespread transmission.
Eric Le Forestier, general manager at Naobios, shared:
“Naobios is excited to receive support from the Bill & Melinda Gates Foundation in its drive to accelerate the development and commercialisation of novel vaccines and the sustainable manufacture of existing vaccines.
With our experienced team, BSL3 suite and track record in successfully manufacturing several viral strains of challenge agents, we look forward to delivering on this project.”